Latest Roswell Park Cancer Institute Stories
BUFFALO, N.Y., April 25 /PRNewswire-FirstCall/ -- Cleveland BioLabs (CBLI) announces the following Webcast: What: Cleveland Biolabs Investor Update Call When: April 28, 2010 @ 10:00 AM Eastern Where: http://www.investorcalendar.com/ClientPage.asp?ID=157342 Live over the Internet --Simply log on to the web at the address How: above. Contact: Rachel Levine, 646-284-9439, email@example.com If you are unable to participate during the live...
BUFFALO, N.Y., April 14 /PRNewswire/ -- Kinex Pharmaceuticals (Buffalo, NY) is scheduled to make four presentations at the 101st Annual Meeting of the American Association for Cancer Research (AACR) that will take place at the Walter E.
Dr. Brian G.M. Durie, co-founder and chair of the International Myeloma Foundation (IMF), heads consortium of investigators across U.S. LOS ANGELES, April 12 /PRNewswire-USNewswire/ -- Aptium Oncology, Inc.
Mammograms, pap smears and early detection tests for prostate cancer, colorectal cancer and other malignancies are critical for catching cancer before it becomes deadly.
DETROIT, Jan. 29 /PRNewswire-USNewswire/ -- After a 10-month nationwide search, Gerold Bepler, M.D., Ph.D., has been named the new president and chief executive officer of the Barbara Ann Karmanos Cancer Institute. A thoracic oncologist, Dr. Bepler will begin his new position Feb. 1, 2010.
NCCN updates the NCCN Guidelines for Non-Small Cell Lung Cancer to include guidance on maintenance therapy, several new therapeutic recommendations for specific patients with Non-Small Cell Lung Cancer, and a revised staging system. FORT WASHINGTON, Pa., Dec.
SOUTHBRIDGE, Mass., Dec.
Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL). FORT WASHINGTON, Pa., Nov.
NCCN program on Discovery Health Channel profiles patients undergoing treatment for metastatic breast cancer and their physicians' use of the NCCN Clinical Practice Guidelines in Oncology(TM) for Breast Cancer to determine an individualized treatment regimen.
NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors.